SeaStar Medical Holding Corp. is pioneering breakthrough medical technologies designed to address life-threatening conditions characterized by hyperinflammation, with a strategic focus on organ-saving therapeutic interventions.
The company's first therapy, QUELIMMUNE, received FDA approval for treating pediatric patients experiencing acute kidney injury (AKI) related to sepsis. Currently, SeaStar is conducting a clinical trial evaluating its second proprietary Selective Cytopheretic Device (SCD) therapeutic for adult AKI patients, representing a potential $4.5 billion annual market opportunity.
Key to the company's approach is its multiple Breakthrough Device Status designations from the FDA, which signal the potential significant medical impact of its technologies. By targeting serious, life-threatening conditions, SeaStar aims to develop treatments that could substantially improve patient outcomes and medical interventions.
The ongoing adult AKI trial, which is already halfway through participant enrollment, demonstrates the company's commitment to expanding treatment options for critically ill patients. SeaStar's strategy of developing broadly applicable therapies positions them at the forefront of innovative medical device development.
